Tonix Pharmaceuticals Holding Corp. (TNXP)
Largest Insider Buys in Sector
TNXP Stock Price History Chart
TNXP Stock Performance
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Insider Activity of Tonix Pharmaceuticals Holding Corp.
Over the last 12 months, insiders at Tonix Pharmaceuticals Holding Corp. have bought $0 and sold $0 worth of Tonix Pharmaceuticals Holding Corp. stock.
On average, over the past 5 years, insiders at Tonix Pharmaceuticals Holding Corp. have bought $61,170 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $34,200 was made by LEDERMAN SETH (Chief Executive Officer) on 2022‑06‑29.
List of Insider Buy and Sell Transactions, Tonix Pharmaceuticals Holding Corp.
| 2022-06-29 | LEDERMAN SETH | Chief Executive Officer | 20,000 0.0147% | $1.71 | $34,200 | -66.14% | ||
| 2022-03-25 | LEDERMAN SETH | Chief Executive Officer | 100,000 0.0033% | $0.24 | $24,500 | -85.39% | ||
| 2021-09-28 | LEDERMAN SETH | Chief Executive Officer | 12,000 <0.0001% | $0.61 | $7,320 | -66.66% | ||
| 2021-05-25 | Goodman Daniel Wintner | director | 5,000 <0.0001% | $1.12 | $5,600 | -56.78% | ||
| 2021-03-24 | LEDERMAN SETH | Chief Executive Officer | 16,733 <0.0001% | $1.32 | $22,088 | -51.21% | ||
| 2020-12-30 | LEDERMAN SETH | Chief Executive Officer | 35,000 0.0001% | $0.68 | $23,800 | +41.83% | ||
| 2020-08-31 | Treco James | director | 5,500 <0.0001% | $0.89 | $4,895 | +9.38% | ||
| 2020-08-20 | Bell Margaret Smith | director | 5,391 <0.0001% | $0.93 | $4,997 | +4.67% | ||
| 2020-08-17 | SULLIVAN GREGORY M | Chief Medical Officer | 20,000 <0.0001% | $1.03 | $20,600 | -5.45% | ||
| 2020-08-14 | Treco James | director | 4,500 <0.0001% | $1.06 | $4,770 | -4.06% | ||
| 2020-08-13 | LEDERMAN SETH | Chief Executive Officer | 60,000 0.0002% | $0.91 | $54,600 | -14.11% | ||
| 2020-08-13 | BAGGER RICHARD H | director | 10,000 <0.0001% | $0.91 | $9,100 | -14.11% | ||
| 2020-08-13 | OLUKOTUN ADEOYE Y | director | 5,350 <0.0001% | $0.94 | $5,029 | -14.11% | ||
| 2019-12-03 | LEDERMAN SETH | Chief Executive Officer | 20,000 1.2754% | $1.16 | $23,180 | -33.19% | ||
| 2019-03-29 | LEDERMAN SETH | Chief Executive Officer | 5,000 0.0005% | $2.49 | $12,440 | -82.15% | ||
| 2019-03-26 | LEDERMAN SETH | Chief Executive Officer | 25,000 0.0025% | $2.38 | $59,375 | -82.14% | ||
| 2018-06-29 | LEDERMAN SETH | Chief Executive Officer | 500 <0.0001% | $4.64 | $2,320 | -94.76% | ||
| 2018-06-28 | LEDERMAN SETH | Chief Executive Officer | 500 <0.0001% | $4.58 | $2,290 | -94.91% | ||
| 2018-06-27 | LEDERMAN SETH | Chief Executive Officer | 500 <0.0001% | $4.55 | $2,275 | -94.91% | ||
| 2018-06-25 | MARIO ERNEST | director | 16,500 0.001% | $4.48 | $73,920 | -94.75% |
Insider Historical Profitability
| Moss David J | PRES, CEO, TRES, CFO, SECR | 3250000 4.0215% | $1.13 | 1 | 0 | |
| DAUGHERTY BRUCE | See remarks | 100000 0.1237% | $1.13 | 6 | 0 | |
| Saks Samuel R | director | 51050 0.0632% | $1.13 | 3 | 0 | |
| MARIO ERNEST | director | 50000 0.0619% | $1.13 | 17 | 7 | |
| LEDERMAN SETH | Chief Executive Officer | 24235 0.03% | $1.13 | 40 | 0 | <0.0001% |
| Rhodes John B | director | 23470 0.029% | $1.13 | 5 | 0 | |
| SULLIVAN GREGORY M | Chief Medical Officer | 21405 0.0265% | $1.13 | 6 | 0 | <0.0001% |
| GERSHELL LELAND | Chief Financial Officer | 19260 0.0238% | $1.13 | 8 | 0 | |
| MATHER CHARLES E IV | director | 11830 0.0146% | $1.13 | 4 | 0 | |
| Treco James | director | 10000 0.0124% | $1.13 | 2 | 0 | +2.66% |
| BAGGER RICHARD H | director | 10000 0.0124% | $1.13 | 1 | 0 | <0.0001% |
| Bell Margaret Smith | director | 5391 0.0067% | $1.13 | 1 | 0 | +4.67% |
| OLUKOTUN ADEOYE Y | director | 5350 0.0066% | $1.13 | 1 | 0 | <0.0001% |
| Goodman Daniel Wintner | director | 5001 0.0062% | $1.13 | 1 | 0 | <0.0001% |
| SAENGER BRADLEY | Chief Financial Officer | 3079 0.0038% | $1.13 | 2 | 0 | |
| MORRIS JESSICA EDGAR | Chief Operating Officer | 1638 0.002% | $1.13 | 1 | 0 |
Institutional Investor Ownership
No records found… | |||||||